-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

Benzinga·10/01/2026 18:28:03
Jefferies analyst Akash Tewari maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $870 to $930.